Name: Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Product comparison
Published: 2026-09-21T21:39:21-04:00

Product information and disease description Product description Product information

Product comparison

5 evidence topics · 3 sources

Comparator epinephrine products marketed in the United States

“Among these are needle device-based treatments that have been accepted as standard of care treatment for many years, including autoinjectors such as EpiPen® marketed by Teva, and generics of EpiPen marketed by Viatris, Inc., Adrenaclick® marketed by Amneal Pharmaceuticals, LLC, and Auvi-Q® marketed by Kaleo Inc. and syringe device Symjep® marketed by U.S. Worldmeds.” (opens the source at this quote in a new tab)
“In August 2024, ARS Pharmaceuticals, Inc. announced its product neffy®, a nasal spray epinephrine delivery device, was approved by the FDA and EMA for the treatment of severe allergic reactions, including anaphylaxis.” (opens the source at this quote in a new tab)

Route, portability, and needle-free status versus auto-injectors

“Auto-injectors can be inconvenient to transport and many patients and caregivers dislike injections as a delivery method.” (opens the source at this quote in a new tab)
“We believe Anaphylm is well positioned as a non-device based treatment option for this indication, if approved by the FDA, due to its comparable efficacy to existing auto-injector and nasal spray products, easy portability and convenience of use.” (opens the source at this quote in a new tab)

“A small, highly portable and needle-free treatment option has the potential to address important barriers associated with carrying and administering epinephrine.” (opens the source at this quote in a new tab)

Device-related limitations of epinephrine auto-injectors

“EAI device-related issues deter device carriage, increase the chances of leaving them at home, make them less accessible when needed and reduce the likelihood of carrying two devices.” (opens the source at this quote in a new tab)

Comparison with epinephrine nasal spray: no head-to-head data

“No head-to-head studies have been conducted comparing Anaphylm and Neffy®.” (opens the source at this quote in a new tab)
“Median T-max of 12 minutes” (opens the source at this quote in a new tab)
“Therapeutic blood concentrations in as little as 5 minutes (over 100 pg/ml)” (opens the source at this quote in a new tab)

Preference survey comparing the film with a nasal spray device

“96% of survey respondents preferred Anaphylm in a hands-on epinephrine preference survey” (opens the source at this quote in a new tab)